High-resolution computed tomography findings independently predict epidermal growth factor receptor mutation status in ground-glass nodular lung adenocarcinoma

Table 1 Baseline and clinical characteristics

	Mutant EGFR group (n = 31)	Wild-type group (n = 67)	P value
Age (yr)	66.6 ± 14.2	62.7 ± 15.6	0.221
< 60	13 (41.9%)	37 (55.2%)
≥ 60	18 (58.1%)	30 (44.8%)
Male	12 (38.7%)	30 (44.8%)	0.573
Smoking history	8 (25.8%)	24 (35.8%)	0.326
Nodule property			0.372
Pure GGNs	7 (22.6%)	21 (31.3%)
Partial solid nodules	24 (77.4%)	46 (68.7%)
Histopathologic diagnosis			0.723
Preinvasive lesions (AAH + AIS)	5 (16.1%)	9 (13.4%)
Invasive lesions (MIA + IPA)	26 (83.9%)	58 (86.6%)
Position of the nodule			0.471
Right upper lobe	10 (32.3%)	27 (40.3%)
Right middle lobe	4 (12.9%)	8 (11.9%)
Right lower lobe	6 (19.4%)	9 (13.4%)
Left upper lobe	5 (16.1%)	17 (25.4%)
Left lower lobe	6 (19.4%)	6 (9.0%)
Time between CT scan and surgery (days)	7.0 (4.5, 13.5)	8.0 (6.0, 13.0)	0.545

EGFR: Epidermal growth factor receptor; GGN: Ground-glass nodule; AAH: atypical adenomatoid hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IPA: invasive pulmonary adenocarcinoma.